Alector (ALEC) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Alector (ALEC) over the past year, gaining 12.8% versus a loss of 34.4%. Over five years, ALEC leads with a -91.3% price change compared with -97.8% for DTIL. Alector is the larger company by market cap ($225.5 million vs $177.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | DTIL |
|---|---|---|
| Share price | $2.02 | $6.43 |
| Market cap | $225.55M | $177.48M |
| 1-day change | +5.21% | +2.88% |
| YTD return | +29.49% | +54.57% |
| 1-year return | -34.42% | +12.81% |
| 5-year return | -91.33% | -97.81% |
| EPS (TTM) | $-1.09 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $9.62 |
| 52-week low | $1.09 | $3.53 |
| Distance from 52-week high | -40.59% | -33.16% |
| Analyst consensus | hold | none |
| Avg. price target upside | +63.37% | +357.23% |
| Average volume | 2.86M | 287.13K |
| Shares outstanding | 111.66M | 27.60M |
| Employees | 103 | 67 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed ALEC by 47.2 percentage points over the past year.
- The two companies sit in different sectors: Alector in Healthcare and Precision BioSciences in Health Care.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Healthcare · Biotechnology · 103 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
ALEC vs DTIL FAQ
Which is bigger, Alector or Precision BioSciences?
Alector (ALEC) is larger, with a market capitalization of $225.55M compared with $177.48M for Precision BioSciences (DTIL).
Which stock has performed better over the past year, ALEC or DTIL?
DTIL returned +12.81% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Precision BioSciences in the same industry?
No. Alector is in the Healthcare sector, while Precision BioSciences is in Health Care.